A dexamethasone-sparing regimen involving lenalidomide (Revlimid) and the anti-CD38 drug daratumumab (Darzalex) was safe and ...

Low-dose nivolumab (Opdivo) plus lenalidomide (Revlimid) yielded a promising response with a favorable safety profile in patients with classical Hodgkin lymphoma (cHL), according to a single-arm phase ...

Labroots is the leading scientific social networking website, offering top scientific trending news and premier educational virtual events and webinars. Contributing to the advancement of science ...

The Subject Expert Committee (SEC - Oncology) under the Central Drugs Standard Control Organization (CDSCO) has requested ...

"This is what I had to do. My mother gave me my grandmother's silver, and I cashed it in to pay for my medical bills," ...

Drugmaker Bristol Myers Squibb said on Friday it will acquire privately held cell therapy developer Orbital Therapeutics for ...

Natco Pharma has secured yet another favourable ruling against a drug innovator, allowing it to sell a generic version of a ...

Bristol Myers Squibb <a href=" target="_blank">(BMY.N) said on Monday that its current drug pipeline has the ability to replace up to $25 billion a year in lost revenue from patent expirations by the ...

Bristol Myers gains FDA Fast Track status for its Alzheimer's antibody BMS-986446 as Cobenfy drives early sales and pipeline ...

Lenalidomide is a cornerstone therapy for multiple myeloma (MM) and other hematologic malignancies, but conventional oral dosing is limited by high peak plasma concentrations, rapid clearance, and ...

Bristol-Myers Squibb (NYSE:BMY) and Fiserv (NYSE:FI) have been getting plenty of attention from big name investors.  Every ...

Teva Pharmaceutical Industries is regaining investor interest as restructuring efforts drive margin improvements. Read why ...